Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Input metadata referenced "Vericel Corp," but the filing text identifies the registrant as Aastrom Biosciences, Inc.)
Reporting Period: Quarter ended September 30, 2007 (Fiscal Year 2008 Q1).
Status: Development-stage company focused on regenerative medicine using autologous cell products (TRC Technology). The company has never been profitable and relies on equity financing and grants.
Key Financial Metrics
| Metric | Q1 FY2008 (Sep 30, 2007) | Q1 FY2007 (Sep 30, 2006) |
|---|---|---|
| Total Revenues | $87,000 | $104,000 |
| Net Loss | $(5,050,000) | $(4,057,000) |
| Loss Per Share (Basic/Diluted) | $(0.04) | $(0.03) |
| Cash and Cash Equivalents | $24,300,000 | $11,724,000 (End of prior period) |
| Total Current Assets | $26,745,000 | $30,177,000 (Prior Balance Sheet Date) |
| Total Current Liabilities | $3,504,000 | $3,500,000 (Prior Balance Sheet Date) |
| Long-Term Debt | $989,000 | $1,097,000 (Prior Balance Sheet Date) |
| Accumulated Deficit | $(164,794,000) | $(159,744,000) (Prior Balance Sheet Date) |
Note: Financial figures are in thousands unless otherwise noted. The company held no short-term investments as of September 30, 2007, having liquidated them during the quarter.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 16% to $87,000, driven by a drop in grant revenues from $92,000 to $75,000 due to reduced NIH grant activities. Product sales remained flat at $12,000.
- Increased Net Loss: Net loss widened by approximately $1 million to $5.05 million. This was primarily due to a 68% increase in Research and Development (R&D) expenses to $3.87 million, reflecting expanded clinical trial activities and headcount.
- SG&A Reduction: Selling, general, and administrative expenses decreased 32% to $1.61 million, largely due to the absence of severance and employment agreement accruals for former executives that occurred in the prior year.
- Liquidity Position: Cash and cash equivalents increased to $24.3 million from $13.4 million at the end of the prior fiscal year (June 30, 2007), despite operating cash burn, due to the liquidation of short-term investments and proceeds from stock exercises.
Guidance, Outlook, and Risks
- Clinical Progress:
- Bone Regeneration: Positive final results reported for non-union fractures (91% healing rate). Phase III ON-CORE trial for osteonecrosis of the femoral head is enrolling in the U.S. and Spain.
- Vascular Regeneration: RESTORE-CLI Phase IIb trial for critical limb ischemia is enrolling. Positive interim data reported from a German trial for diabetic foot wounds.
- Cardiac/Neural: Preclinical research underway; clinical programs expected to begin in fiscal 2008.
- Capital Resources: Management expects monthly cash utilization to average $1.7 million in fiscal 2008. The company does not expect positive cash flows for several years.
- Subsequent Financing: On October 17, 2007, the company closed a registered direct offering raising approximately $12.5 million in net proceeds.
- Key Risks:
- Funding: Continued need for substantial capital to complete clinical trials and commercialization.
- Regulatory: Uncertainty regarding FDA and EU regulatory classifications for cell products; potential delays in approvals.
- Manufacturing: Reliance on third-party suppliers for critical components and a single third-party manufacturer in Germany for EU trials.
- Stock Price: Volatility and risk of delisting from Nasdaq if the bid price falls below $1.00.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $12.5 million raised in October 2007 against the projected $1.7 million monthly burn rate.
- Clinical Trial Enrollment: Monitor patient accrual rates for the ON-CORE (bone) and RESTORE-CLI (vascular) trials, as delays could significantly increase costs.
- Regulatory Status: Track FDA and EU regulatory decisions regarding the classification of TRC-based products as biologics versus other categories.
- Stock Dilution: Assess the impact of future equity issuances required to fund operations, given the company's history of financing through stock sales.
- Third-Party Dependencies: Evaluate the stability of supply chains for animal-derived materials (e.g., fetal bovine serum) and the performance of the German manufacturing partner.